

Blaise A Clarke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3633885/blaise-a-clarke-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

7,339
citations

45
h-index

84
g-index

148
ext. papers

8,688
ext. citations

7.1
avg, IF

5.27
L-index

#	Paper	IF	Citations
145	Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.. <i>Journal of Ovarian Research</i> , 2022 , 15, 50	5.5	0
144	Placenta increta mimicking placental site trophoblastic tumor. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1481-1485	3.5	1
143	Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 116-123	3.2	13
142	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , 2021 , 161, 221-227	4.9	0
141	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021 , 127, 2409-2422	6.4	14
140	Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e22525-e22525	2.2	
139	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. <i>Cancer</i> , 2021 , 127, 3082-3091	6.4	2
138	Can variant negative be high-grade serous ovarian carcinoma? A case series. <i>Gynecologic Oncology Reports</i> , 2021 , 36, 100729	1.3	
137	Validation of BRCA testing on cytologic samples of high-grade serous carcinoma. <i>Cancer Cytopathology</i> , 2021 , 129, 907-913	3.9	1
136	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. <i>Mod Pathol</i> 2020; 33:871-879. <i>Modern Pathology</i> , 2021 , 34, 1031-1032	9.8	3
135	Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program. <i>Molecular Oncology</i> , 2021 , 15, 80-90	7.9	7
134	Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. <i>JAMA Surgery</i> , 2021 , 156, 157-164	5.4	35
133	An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 242-252	5.1	5
132	Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100363	2	0
131	IL6 Induces an IL22 CD8 T-cell Subset with Potent Antitumor Function. <i>Cancer Immunology Research</i> , 2020 , 8, 321-333	12.5	10
130	Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1951-1958	3.5	2
129	Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1523-1523	2.2	1

128	Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. <i>Modern Pathology</i> , 2020 , 33, 1207-1219	9.8	24
127	Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	17
126	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 539-545	4.9	3
125	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. <i>Cancer</i> , 2020 , 126, 4886-4894	6.4	5
124	Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. <i>Onc Immunology</i> , 2019 , 8, e1665460	7.2	13
123	Neoadjuvant therapy in gynaecological malignancies: What pathologists need to know. <i>Journal of Clinical Pathology</i> , 2019 , 72, 102-111	3.9	1
122	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019 , 10, 558	17.4	42
121	Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review. <i>Diagnostic Pathology</i> , 2019 , 14, 30	3	3
120	mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 346-352	3.5	21
119	N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. <i>Cell Systems</i> , 2019 , 8, 345-351.e4	10.6	11
118	Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. <i>Modern Pathology</i> , 2019 , 32, 1823-1833	9.8	28
117	High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation 2019 , 7, 357		27
116	Expanding the morphological spectrum of ovarian microcystic stromal tumour. <i>Histopathology</i> , 2019 , 74, 443-451	7.3	9
115	International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. <i>International Journal of Gynecological Pathology</i> , 2019 , 38 Suppl 1, S114-S122	3.2	20
114	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. <i>American Journal of Pathology</i> , 2018 , 188, 1120-1131	5.8	18
113	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). <i>Pathology</i> , 2018 , 50, 222-237		17
112	Genomic profiling identifies amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 69-78	5.3	8
111	Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5685-5696	12.9	46

110	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , 2018 , 24, 6168-6174	12.9	30
109	Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 137-139	6.7	17
108	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018 , 4, e173776	13.4	72
107	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. <i>Genome Medicine</i> , 2018 , 10, 81	14.4	46
106	Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. <i>Histopathology</i> , 2017 , 70, 1147-1154 ²³	7.3	23
105	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1240-1249	2.2	59
104	A distinct innate lymphoid cell population regulates tumor-associated T cells. <i>Nature Medicine</i> , 2017 , 23, 368-375	50.5	97
103	Ovarian carcinoma histotype in Lynch syndrome. <i>Gynecologic Oncology Reports</i> , 2017 , 20, 140-141	1.3	1
102	VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. <i>British Journal of Cancer</i> , 2017 , 116, 1065-1076	8.7	14
101	The predictive value of nadir neutrophil count during treatment of cervical cancer: Interactions with tumor hypoxia and interstitial fluid pressure (IFP). <i>Clinical and Translational Radiation Oncology</i> , 2017 , 6, 15-20	4.6	10
100	Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017 , 39, 659-667	1.3	9
99	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 71-83	1.1	6
98	DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 1178-1187	6.7	60
97	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2017 , 23, 925-934	12.9	89
96	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5522-5522	2.2	3
95	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017 , 8, 84659-84670	3.3	12
94	Uterine Clear Cell Carcinoma. <i>Molecular Pathology Library</i> , 2017 , 123-142		
93	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149

92	Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers. <i>Surgical Pathology Clinics</i> , 2016 , 9, 307-28	3.9	2
91	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 111-117	4	21
90	Precursors of High-Grade Serous Carcinoma 2016 , 3-22		
89	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016 , 141, 148-54	4.9	26
88	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1532-1532	2.2	2
87	Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5509-5509	2.2	
86	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5579-5579	2.2	
85	Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5564-5564	2.2	
84	P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5550-5550	2.2	
83	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i> , 2016 , 69, 727-738	7.3	40
82	Ovarian hilar proliferations resembling Sertoli cell tumours: microscopic neoplasms or non-neoplastic remnants?. <i>Histopathology</i> , 2016 , 68, 596-602	7.3	3
81	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016 , 141, 559-563	4.9	19
80	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015 , 28, 1101-22	9.8	107
79	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. <i>Gynecologic Oncology</i> , 2015 , 137, 216-22	4.9	48
78	Chromosomal instability as a prognostic marker in cervical cancer. <i>BMC Cancer</i> , 2015 , 15, 361	4.8	12
77	Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015 , 139, 268-74	4.9	35
76	Microscopic extraovarian sex cord proliferations: an undescribed phenomenon. <i>Histopathology</i> , 2015 , 66, 555-64	7.3	19
75	Mutations in IDH1 and IDH2 are not present in sporadic ovarian sex cord-stromal tumours. <i>Histopathology</i> , 2015 , 66, 897-8	7.3	

74	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 173-85	5.3	51
73	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. <i>Gynecologic Oncology</i> , 2015 , 136, 311-6	4.9	6
72	A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3061-3061	2.2	11
71	Developing a prognostic micro-RNA signature for human cervical carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0123946	3.7	24
70	Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1532-1532	2.2	
69	Molecular profiling and targeted therapy in advanced endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5589-5589	2.2	
68	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014 , 32, 243-9	4.3	63
67	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. <i>Journal of Pathology</i> , 2014 , 232, 473-81	9.4	68
66	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. <i>Nature Genetics</i> , 2014 , 46, 438-43	36.3	305
65	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. <i>Nature Genetics</i> , 2014 , 46, 427-9	36.3	224
64	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014 , 46, 1166-9	36.3	150
63	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014 , 27, 255-61	9.8	86
62	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , 2014 , 120, 3932-9	6.4	87
61	Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low-versus high-volume ascites. <i>BioMed Research International</i> , 2014 , 2014, 367103	3	20
60	Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 629-33	1.9	9
59	Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. <i>Histopathology</i> , 2014 , 65, 228-39	7.3	20
58	No small surprise—small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. <i>Journal of Pathology</i> , 2014 , 233, 209-14	9.4	101
57	Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 845-56	5	102

56	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. <i>Cancer</i> , 2014 , 120, 603-10	6.4	58
55	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. <i>BMC Cancer</i> , 2014 , 14, 982	4.8	21
54	The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 1173-81	6.7	87
53	Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. <i>International Journal of Gynecological Pathology</i> , 2014 , 33, 560-7	3.2	21
52	Displaced granulosa cells within the ovarian stroma in a BRCA1 mutation carrier. <i>International Journal of Gynecological Pathology</i> , 2014 , 33, 423-4	3.2	2
51	Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. <i>Gynecologic Oncology</i> , 2014 , 133, 229-33	4.9	57
50	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. <i>Human Pathology</i> , 2014 , 45, 1258-68	3.7	28
49	Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5506-5506	2.2	1
48	Adjuvant radiation for patients (pts) with high-grade serous ovarian cancer (HGSC) and T-cell infiltration.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5543-5543	2.2	
47	The CXCL12/CXCR4 pathway, bone marrow-derived myeloid cells, and survival in locally advanced cervical cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11122-11122	2.2	
46	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013 , 31, 1182-91	4.3	45
45	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , 2013 , 14, 853-62	21.7	248
44	The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 721-7	4	12
43	Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. <i>Gynecologic Oncology</i> , 2013 , 131, 634-9	4.9	26
42	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. <i>Journal of Pathology</i> , 2013 , 229, 111-20	9.4	139
41	Neuroendocrine tumors of the gynecologic tract: select topics. <i>Seminars in Diagnostic Pathology</i> , 2013 , 30, 224-33	4.3	42
40	Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors. <i>Modern Pathology</i> , 2013 , 26, 95-105	9.8	39
39	Hypoxic activation of the PERK/eIF2 β arm of the unfolded protein response promotes metastasis through induction of LAMP3. <i>Clinical Cancer Research</i> , 2013 , 19, 6126-37	12.9	85

38	Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. <i>Advances in Anatomic Pathology</i> , 2013 , 20, 378-86	5.1	44
37	A triage assessment strategy for the management of women with endometrial cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013 , 35, 348-354	1.3	
36	Biologically-targeted detection of primary and micro-metastatic ovarian cancer. <i>Theranostics</i> , 2013 , 3, 420-7	12.1	23
35	MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. <i>PLoS ONE</i> , 2013 , 8, e67846	3.7	52
34	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11002-11002	2.2	8
33	Screening for Lynch syndrome in unselected women with endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5508-5508	2.2	
32	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012 , 10, 33	8.5	85
31	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012 , 118, 681-8	6.4	62
30	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1503-13	9.7	191
29	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012 , 10, 205	8.5	538
28	Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 767-75	14.4	37
27	Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. <i>Cancer</i> , 2012 , 118, 3105-15	6.4	47
26	Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). <i>Cancers</i> , 2012 , 4, 821-45	6.6	34
25	Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. <i>International Journal of Gynecological Pathology</i> , 2012 , 31, 524-31	3.2	51
24	Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. <i>Advances in Anatomic Pathology</i> , 2012 , 19, 231-8	5.1	45
23	Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. <i>New England Journal of Medicine</i> , 2012 , 366, 234-42	59.2	332
22	Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5010-5010	2.2	5
21	Prognostic significance of high-risk human papilloma virus (HPV), p16, and p53 status in women with vulvar squamous cell carcinoma (VSCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5105-5105	2.2	

20	Brief family history questionnaire for identification of Lynch syndrome in women with newly diagnosed endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5026-5026	2.2	
19	Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. <i>Cancer Research</i> , 2011 , 71, 3364-76	10.1	563
18	Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 115-26	6.7	59
17	Tubulo-squamous polyp with mucinous and goblet cell differentiation: a unique morphologic variant. <i>International Journal of Gynecological Pathology</i> , 2011 , 30, 518-9	3.2	10
16	Ovarian immature teratoma: treatment and outcome in a single institutional cohort. <i>Gynecologic Oncology</i> , 2011 , 123, 50-3	4.9	28
15	In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. <i>Journal of Proteome Research</i> , 2011 , 10, 2286-99	5.6	63
14	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011 , 24, 512-21	9.8	79
13	Letter to the editor regarding @oh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expressionQ <i>Modern Pathology</i> , 2011 , 24, 1281-2; author reply 1282-3	9.8	6
12	Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. <i>Journal of Clinical Pathology</i> , 2010 , 63, 410-5	3.9	72
11	Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 1132-8	6.7	14
10	Leiomyosarcoma of the broad ligament with osteoclast-like giant cells and rhabdoid cells. <i>International Journal of Gynecological Pathology</i> , 2010 , 29, 432-7	3.2	5
9	Cryptococemia resulting in an incomplete abortion in an HIV-positive patient. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009 , 20, e97-9	2.6	3
8	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. <i>Modern Pathology</i> , 2009 , 22, 393-402	9.8	196
7	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. <i>Human Pathology</i> , 2009 , 40, 1070-81	3.7	117
6	Mutation of FOXL2 in granulosa-cell tumors of the ovary. <i>New England Journal of Medicine</i> , 2009 , 360, 2719-29	59.2	551
5	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. <i>Seminars in Diagnostic Pathology</i> , 2009 , 26, 165-76	4.3	25
4	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008 , 39, 1239-51	3.7	207
3	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. <i>Modern Pathology</i> , 2007 , 20, 1156-65	9.8	56

- 2 Clear cell (glycogen-rich) gastric adenocarcinoma. *Annals of Diagnostic Pathology*, **2004**, 8, 69-73 2.2 24
- 1 Systemic anaplastic large cell lymphoma presenting with conjunctival involvement. *JAMA Ophthalmology*, **2003**, 121, 568-70 29